📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol. (2023)

First Author: McClure ME

Attributed to: A mechanistic study of rituximab and belimumab combination therapy in PR3 ANCA-associated vasculitis funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1186/s13063-023-07218-y

PubMed Identifier: 36906660

Publication URI: http://europepmc.org/abstract/MED/36906660

Type: Journal Article/Review

Volume: 24

Parent Publication: Trials

Issue: 1

ISSN: 1745-6215